Humanigen Inc

Humanigen — Investor Presentation (August 2020)

19 slides from Humanigen's investor presentation, Aug 10, 2020

  1. Slide 1: Humanigen August 2020

    0 “Therapeutics with the best data reported in the past month are remdesivir , lenzilumab and dexamethasone.” BioWorld , July 2020, reporting on COVID - 19 therapeutics Confidential Humanigen August 2020

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    1 Cautionary Note Regarding Forward - Looking Statements Certain statements, beliefs and opinions in this presentation are forward looking, which reflect current expectations and pro jec tions about future events. Forward - looking statements reflect management's current knowledge, assumptions, judg

  3. Slide 3: Experienced and Execution-Oriented Management

    2 Experienced and Execution - Oriented Management Dale Chappell, MD, MBA – Chief Scientific Officer n Founder, Black Horse Capital Advisors; decades of biotech investment experience n Head of healthcare portfolio, Chilton Investment Company n Multiple publications in T - cell therapy, GM - CSF, immu

  4. Slide 4: Company Highlights

    3 Company Highlights Leading expertise in Cytokine Storm across multiple therapeutic applications; p artnership in cytokine storm with Kite/Gilead Strong mid - to - late stage clinical pipeline including potential registration studies in CAR - T and GvHD, both majority funded by development partner

  5. Slide 5: Clinical-Stage Pipeline: Lenzilumab in COVID-19

    4 Clinical - Stage Pipeline: Lenzilumab in COVID - 19 Indication Phase Status Centers Partners Lenzilumab COVID - 19 Prevention/treatment of Cytokine Storm III Actively r ecruiting 300 patients (>50% enrolled) ~15 - 20 sites Company sponsored COVID - 19 Prevention/treatment of Cytokine Storm III R e

  6. Slide 6: Clinical-Stage Pipeline: Non-COVID

    5 Clinical - Stage Pipeline: Non COVID - 19 1 Phase III may not be necessary for approval in ZUMA - 19; precedent is CAR - Ts to date have been approved on Phase II data 2 UK 3 US, EU, Australia 4 Australia Indication Phase Status Centers Partners Lenzilumab ZUMA - 19: Break CAR - T Efficacy/Toxicit

  7. Slide 7: Key Corporate and Lenzilumab in COVID-19 Milestones

    6 Key Corporate and Lenzilumab in COVID - 19 Milestones H1 □ Expanded launch and commercialization □ Announce key hires H2 □ Life cycle management: ▪ New patient segments ▪ Label expansion ▪ Additional dose formulations ▪ Further international studies Q3 □ NIH fully - sponsored 200 patient study ( l

  8. Slide 8: Pipeline Key Non-COVID Milestones

    7 Pipeline Key Non - COVID Milestones H1 □ ZUMA - 19 (CAR - T) Phase II interim analysis □ Additional CAR - T studies □ Ifabotuzumab Phase I results □ GvHD study commencement (UK) □ CMML study commencement (Australia) H2 □ ZUMA - 19 (CAR - T) six - month efficacy data □ Complete planning for GvHD st

  9. Slide 9: Agenda

    8 Agenda Therapeutic for COVID - 19 Patients Improving efficacy / safety of CAR - T 1 2 3 4 Prevention / Treatment of Acute GvHD 4

  10. Slide 10: Lung Injury Induced Through Cytokine Storm: Key Stages of Disease Progression

    9 Lung Injury Induced Through Cytokine Storm: 3 Key Stages of Disease Progression Adapted from: doi: 10.1016/j.healun.2020.03.012 Acute viral symptoms of fever, muscle pain, fatigue, cough Shortness of breath hypoxia Respiratory failure, cardiac failure, neurological changes, DIC, multi organ failur

  11. Slide 11: Compassionate Use Program (CUP)

    10 Compassionate Use Program (CUP) n CUP conducted at Mayo Clinics, leading COVID - 19 expert centers with choice of industry - wide research n Under auspices of hospital system COVID - 19 task force leader and senior physician n Patient characteristics similar to intended Phase III and BET entrants

  12. Slide 12: Lenzilumab Cohort Benchmarked vs Remdesivir

    11 Lenzilumab Cohort Benchmarked vs Remdesivir 1 Patient Baseline Characteristics; Days of Treatment 1 day Lenzilumab 5 day Remdesivir 10 day Remdesivir Median age (IQR) 65 (52 - 70) 61 (50 - 69) 62 (50 - 71) Male (%) 67% 60% 68% Race (%) White 75% 71% 70% Black 0% 10% 12% Asian 17% 10% 13% Other 8%

  13. Slide 13: Lenzilumab Displays More Rapid Clinical Improvement

    12 Lenzilumab Displays More Rapid Clinical Improvement 1 0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0% 70.0% 80.0% 90.0% 100.0% D 0 D 1 D 2 D 3 D 4 D 5 D 6 D 7 D 8 D 9 D 1 0 D 1 1 D 1 2 D 1 3 D 1 4 D 1 5 D 1 6 D 1 7 D 1 8 D 1 9 D 2 0 D 2 1 D 2 2 D 2 3 D 2 4 D 2 5 D 2 6 D 2 7 D 2 8 C u m u l a t i v e I n

  14. Slide 14: Primary Endpoint: Time to Recovery by Day

    13 Primary Endpoint: Time to Recovery by Day 28 (Ordinal Scale 6, 7 or 8) Beigel. NEJM. 2020;[Epub]. Clinical Status Ordinal Scale Clinical Status Description for Assessment 8 Not hospitalized, no limitations on activities 7 Not hospitalized, limitation on activities, and/or requiring home oxygen 6

  15. Slide 15: NIH Selected Lenzilumab for its Big Effect Trial

    14 NIH Selected Lenzilumab for its “Big Effect Trial” 4 n Targeting high priority therapeutics with novel mechanisms n Builds on NIAID’s Adaptive COVID - 19 Treatment Trial (ACTT - 1) which lead to EUA for remdesivir n Sponsored and conducted by NIAID n Only the third of five agents selected by NIH

  16. Slide 16: Robust Development Program for Lenzilumab

    15 Robust Development Program for Lenzilumab ▪ 500 Total Patients Expected in COVID - 19 Development Program for Lenzilumab • 300 Patients in Global Phase 3 Development Study of Lenzilumab vs. Placebo in Patients with Severe or Critical COVID - 19 • 200 Patients in NIAID - sponsored Big Effect Trial

  17. Slide 17: ZUMA-19 Potential Registration Study

    16 ZUMA - 19 Potential Registration Study Efficacy Safety Dosing Schedule ▪ 3+3 Design to find recommended phase II dose ▪ Cohort 1 with Starting Dose ▪ Cohort 2 with Escalating Dose Clinical Trial Design Phase Ib Phase II ▪ At Recommended Dose ▪ Complete Response (CR) ▪ Partial Response (PR) ▪ Obje

  18. Slide 18: GvHD Potential Registration Study

    17 Dosing Schedule (every 2 weeks) N= 420 Patients Clinical Trial Design Phase II/III ▪ 6 month NRM ▪ Response rate at day 28 ▪ Progression Free Survival (PFS) ▪ Overall Survival (OS) ▪ Infections Endpoints 6 Months Allo Transplant Ongoing follow - up for safety and efficacy Lenzilumab + SOC vs. Pla

  19. Slide 19: Key Accomplishments and Next Steps

    18 Key Accomplishments and Next steps Complete recruitment in both COVID - 19 studies NASDAQ uplisting Continue CAR - T recruitment, planning for additional CAR - T studies and GvHD study in 2021 Add to recent senior hires (CSO, CAO, COO/CFO) with additional key hires Prepare for commercial launch 1

Humanigen — Investor Presentation (August 2020) on 6ix